BEIJING, Nov. 4, 2019 /PRNewswire/ -- China Biologic
Products Holdings, Inc. (NASDAQ: CBPO) ("China Biologic" or the
"Company"), a leading fully integrated plasma-based
biopharmaceutical company in China, today announced that the
Company plans to release its third quarter 2019 financial results
on Wednesday, November 13, 2019 after the market
closes.
The Company's management will hold a conference call
at 7:30 a.m. ET on Thursday, November 14, 2019,
which is 8:30 p.m. Beijing Time on November 14, to
discuss third quarter 2019 results. Listeners may access the call
by dialing:
|
US:
|
1 888 346
8982
|
|
International:
|
1 412 902
4272
|
|
Hong
Kong:
|
800 905945
|
|
China:
|
4001
201203
|
A telephone replay will be available one hour after the
conclusion of the conference call through November 21, 2019.
The dial-in details are:
|
US:
|
1 877 344
7529
|
|
International:
|
1 412 317
0088
|
|
Passcode:
|
10136730
|
A live and archived webcast of the conference call will be
available through the Company's investor relations website
at http://chinabiologic.investorroom.com/.
About China Biologic Products Holdings, Inc.
China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a
leading fully integrated plasma-based biopharmaceutical company
in China. The Company's products are used as critical
therapies during medical emergencies and for the prevention and
treatment of life-threatening diseases and immune-deficiency
related diseases. China Biologic is headquartered
in Beijing and manufactures over 20 different dosage
forms of plasma products through its indirect majority-owned
subsidiary, Shandong Taibang Biological Products Co., Ltd. and its
wholly owned subsidiary, Guizhou Taibang Biological Products Co.,
Ltd. The Company also has an equity investment in Xi'an Huitian
Blood Products Co., Ltd. Since the acquisition of TianXinFu
(Beijing) Medical Appliance Co.,
Ltd. in 2018, China Biologic is also engaged in the manufacturing
and sale of medical devices, primarily regenerative medical
biomaterial products. The Company sells its products to hospitals,
distributors and other healthcare facilities in China. For
additional information, please see the Company's
website www.chinabiologic.com.
Contact:
China Biologic Products Holdings, Inc.
Mr. Ming Yin
Senior Vice President
Email: ir@chinabiologic.com
The Foote Group
Mr. Philip Lisio
Phone: +86-135-0116-6560
E-mail: phil@thefootegroup.com
View original
content:http://www.prnewswire.com/news-releases/china-biologic-products-to-report-third-quarter-2019-financial-results-300950604.html
SOURCE China Biologic Products Holdings, Inc.